Taysha Gene Therapies Q4 Earnings Call Highlights

1 day ago 6

MarketBeat

Thu, March 19, 2026 astatine 10:47 AM CDT 9 min read

Taysha Gene Therapies logo

Regulatory and proceedings progress: TSHA-102 received FDA Breakthrough Therapy designation, Taysha has initiated the REVEAL pivotal proceedings and obtained clearance for the safety-focused ASPIRE study, with FDA alignment supporting pooling of objective information and a PPQ program to alteration a BLA submission.
Encouraging information and efficacy signals: REVEAL Part A showed beardown responses—100% response crossed 10 treated patients and 83% effect astatine six months successful the high-dose cohort—while absorption reported no treatment-related superior adverse events to the March 2026 cutoff; 12‑month follow-up information are owed successful Q2 2026.
Financial runway and commercialized readiness: 2025 nett nonaccomplishment widened to $109.0 cardinal connected higher R&D/G&A, but Taysha ended the twelvemonth with $319.8 cardinal successful currency positive $50 cardinal raised successful Q4, which absorption says funds operations into 2028 arsenic it builds marketplace entree and prepares for imaginable commercialization (favoring intrathecal delivery).
Interested successful Taysha Gene Therapies, Inc.? Here are 5 stocks we similar better.

Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"

Taysha Gene Therapies (NASDAQ:TSHA) highlighted clinical, regulatory, and commercialized advancement for its pb Rett syndrome cistron therapy programme portion besides reporting higher operating expenses and a wider nett nonaccomplishment for full-year 2025, according to absorption connected the company’s March 19 league call.

Chief Executive Officer Sean Nolan said 2025 was “a twelvemonth of important execution,” pointing to Phase I/II REVEAL information crossed pediatric, adolescent, and big patients, the FDA’s Breakthrough Therapy designation for TSHA-102, and written FDA alignment connected the REVEAL pivotal and ASPIRE proceedings designs. Nolan said those steps “pav[e] the mode for a perchance streamlined way toward BLA submission.”

→ Dollar Tree Planted the Seeds for Triple-Digit Gains successful Q4

3 Small-Cap Stocks For Your Fall Shopping List

The institution initiated the REVEAL pivotal proceedings successful the 4th fourth of 2025 with dosing of the archetypal patient. Nolan said aggregate patients person present been dosed, enrollment is advancing crossed aggregate sites, and Taysha remains connected way to implicit dosing successful the 2nd 4th of 2026.

Management besides emphasized tolerability crossed studies to date. Nolan said some high- and low-dose TSHA-102 person continued to beryllium mostly well-tolerated, with nary treatment-related superior adverse events oregon dose-limiting toxicities observed successful patients treated successful the REVEAL Phase I/II and REVEAL pivotal trials arsenic of the March 2026 information cutoff.

Read Entire Article